COMMUNIQUÉS West-GlobeNewswire

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
16/10/2025
In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years 1 eGFR is key marker of [...]
Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025
16/10/2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports 77% year-over-year increase for the first nine months of 2025 Financial [...]
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025
16/10/2025
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read platforms. Leveraging Roche’s SBX [...]
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
15/10/2025
Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or the [...]
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
15/10/2025
MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
15/10/2025
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today [...]
Teladoc Health to Announce Third Quarter 2025 Financial Results
15/10/2025
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2025 results on Wednesday, October 29, 2025, after the market [...]
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
15/10/2025
WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six [...]
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
15/10/2025
WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose [...]
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025
15/10/2025
WARSAW, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
15/10/2025
SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to Acquire C2 CryoBalloon Technology
15/10/2025
Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders. Asset acquisition is projected to add [...]
PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025
15/10/2025
SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
15/10/2025
Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489 In recognition of the high volume of patient inquiries, [...]
Vara obtient le marquage CE en tant que seule IA autorisée pour une deuxième lecture indépendante en mammographie et se développe en Europe
15/10/2025
BERLIN, 15 oct. 2025 (GLOBE NEWSWIRE) -- Vara a annoncé aujourd'hui avoir reçu un nouveau certificat CE pour sa nouvelle IA d'imagerie mammaire – la seule sur le marché autorisée à effectuer une deuxième lecture [...]
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
15/10/2025
Nasdaq Hearing Cancellation and Continued Listing FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical [...]
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
15/10/2025
Nasdaq Hearing Cancellation and Continued Listing FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical [...]
OSE Immunotherapeutics Reports First Half 2025 Financial Results
15/10/2025
OSE Immunotherapeutics Reports First Half 2025 Financial Results NANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today reported its consolidated financial [...]
OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025
15/10/2025
OSE Immunotherapeutics publie ses résultats financiers du 1 er semestre 2025 Nantes, France, le 15 octobre 2025, 19 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , publie aujourd’hui ses résultats [...]

Pages